Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

PZ0191

Sigma-Aldrich

Crizotinib

Crizotinib

≥98% (HPLC)

Sinônimo(s):

(R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine, PF 2341066, PF-02341066, PF02341066, Xalkori

Faça loginpara ver os preços organizacionais e de contrato

Selecione um tamanho

5 MG
R$ 631,00

R$ 631,00

Check Cart for Availability
Solicite uma grande encomenda
Todas as fotos(1)

Selecione um tamanho

Alterar visualização
5 MG
R$ 631,00

About This Item

Fórmula empírica (Notação de Hill):
C21H22Cl2FN5O
Número CAS:
877399-52-5
Peso molecular:
450.34
Número MDL:
MFCD12407409
Código UNSPSC:
12352200
ID de substância PubChem:
329823765
NACRES:
NA.77

R$ 631,00

Check Cart for Availability
Solicite uma grande encomenda

Ensaio

≥98% (HPLC)

Formulário

powder

cor

white to tan

temperatura de armazenamento

room temp

cadeia de caracteres SMILES

C[C@@H](Oc1cc(cnc1N)-c2cnn(c2)C3CCNCC3)c4c(Cl)ccc(F)c4Cl

InChI

1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1

chave InChI

KTEIFNKAUNYNJU-GFCCVEGCSA-N

Informações sobre genes

human ... ALK(238) , MET(4233)

Aplicação

Crizotinib has been used:
  • to investigate its effects on hepatocyte growth factor receptor (c-Met) expression, proliferation and apoptosis[1]
  • to block neurotrophic tyrosine kinase receptor type 1 (NTRK1) activity in epithelial cells[2]
  • to restore sensitivity to erlotinib[3]

Ações bioquímicas/fisiológicas

ATP-competitive c-MET / ALK Inhibitor
Crizotinib (PF-02341066) is an ATP-competitive inhibitor of the receptor tyrosine kinases (RTKs) c-Met (hepatocyte growth factor receptor) and anaplastic lymphoma kinase (ALK). Crizotinib is a highly specific inhibitor of c-Met and ALK among > 120 different RTKs surveyed. Crizotinib was approved for treatment of a subtype of nonsmall-cell lung cancer (NSCLC) with ALK fusion mutations.

Características e benefícios

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Informações legais

Sold for research purposes under agreement from Pfizer Inc.

Palavra indicadora

Warning

Frases de perigo

H317,H319,H341,H400

Classificações de perigo

Aquatic Acute 1 - Eye Irrit. 2 - Muta. 2 - Skin Sens. 1

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number
0000360769
0000360769
0000187253
034M4739V
091M4718V

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Pesquise por COA

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 9

1 of 9

KT203 ≥98% (HPLC)

Sigma-Aldrich

SML1250

KT203

A 887826 ≥98% (HPLC)

Sigma-Aldrich

SML0345

A 887826

Maraviroc ≥98% (HPLC)

Sigma-Aldrich

PZ0002

Maraviroc

PF-06658607 ≥98% (HPLC)

Sigma-Aldrich

PZ0242

PF-06658607

PHA-665752 hydrate ≥98% (HPLC)

Sigma-Aldrich

PZ0147

PHA-665752 hydrate

Lapatinib ≥98% (HPLC)

Sigma-Aldrich

SML2259

Lapatinib

Sunitinib malate ≥98% (HPLC)

Sigma-Aldrich

PZ0012

Sunitinib malate

Pemetrexed disodium heptahydrate ≥98% (HPLC)

Sigma-Aldrich

SML1490

Pemetrexed disodium heptahydrate

AZD2461 ≥98% (HPLC)

Sigma-Aldrich

SML1858

AZD2461

Shota Yamamoto et al.
Radiology, 272(2), 568-576 (2014-06-03)
To present a radiogenomic computed tomographic (CT) characterization of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) (ALK+). In this HIPAA-compliant institutional review board-approved retrospective study, CT studies, ALK status, and clinical-pathologic data in 172 patients with NSCLC from
Registered report: Widespread potential for growth factor-driven resistance to anticancer kinase inhibitors
Greenfield E, et al.
eLife, 3, e04037-e04037 (2014)
Zheng Liu et al.
Oncoimmunology, 9(1), 1758003-1758003 (2020-09-15)
Despite some of the oncogenic driver mutations that have been associated with increased expression of programmed death-ligand 1 (PD-L1), the correlation between PD-L1 expression and ROS1 fusion in NSCLC cells, especially for those with Crizotinib resistance has not been fully
Nicole R Infarinato et al.
Cancer discovery, 6(1), 96-107 (2015-11-12)
Neuroblastomas harboring activating point mutations in anaplastic lymphoma kinase (ALK) are differentially sensitive to the ALK inhibitor crizotinib, with certain mutations conferring intrinsic crizotinib resistance. To overcome this clinical obstacle, our goal was to identify inhibitors with improved potency that
Neurotrophic tyrosine kinase receptor 1 is a direct transcriptional and epigenetic target of IL-13 involved in allergic inflammation
Rochman M, et al.
Mucosal Immunology, 8(4), 785-785 (2015)
Exibir todos os documentos relacionados

Artigos

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

Discover Bioactive Small Molecules for Kinase Phosphatase Biology

1 Review This action will navigate to reviews.

Questions

Reviews

Active Filters

  1. 1 Ratings-Only Review

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica